Mirai Medical, the lead applicant and coordinating partner, has been awarded €7.2M under the Disruptive Technologies Innovation Fund (DTIF) Call 7 for PIONEER – Pathology and Immuno-Oncology with Next-Generation Screening and Electroporation for Enhanced Response.
Related: Kestra Medical Technologies prices $138M offering
PIONEER is focused on developing next-generation colorectal cancer treatment built on its ePORE® electroporation platform, integrating advanced screening, pathology, molecular profiling and immuno-oncology to improve therapeutic response and preserve organ function.
This award forms part of the Department of Enterprise, Tourism and Employment record-breaking €159M investment in transformative technologies across health, AI, sustainability and advanced engineering, reinforcing Ireland’s commitment to world-leading innovation.
PIONEER is delivered in collaboration with Trinity College Dublin, University of Galway, University College Dublin, Eurofins and Deciphex with clinical studies being completed at St James’s Hospital Dublin, bringing together national expertise from digital pathology, biomarkers, and translational oncology.
